bms focuses on the innovative blood technology industry chain, driven by innovation and grounded in quality. The company is dedicated to original R&D and industrialization of advanced blood medical technologies, replacing imports, reducing costs, and enhancing efficiency for the domestic market while expanding globally. bms has been recognized as a fast-growing gazelle enterprise and a high-tech enterprise for three consecutive years, and has been selected four times for the Optics Valley 3551 High-Level Talent Program. Since obtaining its first registration certificate for innovative medical devices and consumables in 2018, bms secured its second and third sterile tube welding certificates in 2022, and a fourth certificate in 2023 for innovative consumables treating dry eye syndrome. After achieving ISO13485/ISO9001 certifications for medical technology quality systems, bms obtained CE certification for EU export and FDA approval for U.S. export in 2023 .